ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Enhanced antitumor efficacy of sulfasalazine and mesalazine in colorectal cancer through modulatory action of Lacticaseibacillus rhamnosus GG.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) ranks as the second most lethal cancer worldwide. Probiotics have long been utilized to treat gastrointestinal diseases. Probiotics may play a role in the prevention and treatment of CRC. Additionally, the anti-inflammatory drugs sulfasalazine (SSA) and mesalazine (MESA) have a preventive role in CRC. This study investigates the modulatory antitumor effects of combining the probiotic Lacticaseibacillus rhamnosus GG (LGG) with SSA or MESA and the associated molecular mechanisms in CRC. In vitro studies of LGG-CFS, both alone and in combination with SSA or MESA, were assessed in HCT-116 and HT-29 CRC cells. In vivo, 61 albino rats aged 8 weeks were used and CRC was induced using 1,2-dimethylhydrazine. The 1,2-dimethylhydrazine-induced rats were divided into six groups, each of eight-in addition to the negative control group (received phosphate buffer saline only)-as follows: (I) positive control group (received DMH only), (II) SSA-treated group, (III) MESA-treated group, (IV) LGG-treated group, (V) SSA + LGG-treated group, and (VI) MESA + LGG-treated group. Rats received daily oral doses of SSA (250 mg/kg), MESA (62.5 mg/kg), LGG (1 × 10
Indexed as
Identifiers
42301350What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.